🧫 AMTAGVI utilizes patient-specific tumor infiltrating lymphocytes (TIL) to locate and destroy cancer. The FDA's accelerated approval is based on the relevant results published in 2022, with 31.5% of the 73 patients achieving an objective response. https:/
I just recently was asked if I ever heard of this newly approved therapy (Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy) Ever heard of it?!!! Time to press play! Great news for patients! https://
RT @Chrystal_Paulos: Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients…